References
Frohn C, Hoppner M, Schlenke P, Kirchner H, Koritke P, Luhm J . Anti-myeloma activity of natural killer lymphocytes. Br J Haematol 2002; 119: 660–664.
Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105: 251–258.
Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002; 99: 3661–3667.
Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998; 187: 2065–2072.
Acknowledgements
This work was supported by Groupement entreprise française lutte cancer, association pour la recherche contre le cancer, Fédération nationale des centres de lutte contre le cancer, Fondation pour la Recherche Médicale.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Fauriat, C., Mallet, F., Olive, D. et al. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 20, 732–733 (2006). https://doi.org/10.1038/sj.leu.2404096
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404096
- Springer Nature Limited
This article is cited by
-
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model
Cancer Immunology, Immunotherapy (2023)
-
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Journal of Hematology & Oncology (2022)
-
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21
Cancer Immunology, Immunotherapy (2022)
-
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide
Cancer Immunology, Immunotherapy (2020)
-
Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells
Scientific Reports (2017)